Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer
Authors
Keywords
Tumor-infiltrating lymphocytes, Breast cancer, Pertuzumab, HER2, CD8/FOXP3 ratio
Journal
Journal of Translational Medicine
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-04
DOI
10.1186/s12967-018-1460-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
- (2017) Shinichiro Kashiwagi et al. PLoS One
- Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
- (2016) Y. Asano et al. BRITISH JOURNAL OF SURGERY
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer
- (2016) Yayi He et al. CANCER SCIENCE
- Macrophages and cancer: from mechanisms to therapeutic implications
- (2015) Renato Ostuni et al. TRENDS IN IMMUNOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
- (2014) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
- (2014) Hidemi Kawajiri et al. Expert Review of Anticancer Therapy
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer
- (2013) S. Kashiwagi et al. BRITISH JOURNAL OF SURGERY
- Clinical significance of macrophage heterogeneity in human malignant tumors
- (2013) Yoshihiro Komohara et al. CANCER SCIENCE
- The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
- (2012) Catharina Medrek et al. BMC CANCER
- Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer
- (2012) Hui Liu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
- (2011) Makiko Ono et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence
- (2011) Petr Kocián et al. HUMAN IMMUNOLOGY
- Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer
- (2011) Chang Gong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Prognostic significance and mechanism of Treg infiltration in human brain tumors
- (2010) Joannes F.M. Jacobs et al. JOURNAL OF NEUROIMMUNOLOGY
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
- (2008) Dan Zhu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
- (2008) Stephen Chia et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now